ir.mirati.comMirati Therapeutics Inc. - Investor & Media Relations

Mirati Therapeutics Inc. - Investor & Media Relations Investors & Media Overview Careers Contact Us Home Science Pipeline Programs KRAS Inhibitors KRAS G12C Inhibitor KRAS G12D Inhibitor SitravatinibPRMT5 Inhibitor Clinical Trials Presentations & Publications Patients & Caregivers Medicines Responsibility Mirati Gives Transparency Diversity, Equity & Inclusion Sponsorships & Grants Compliance Declaration Stories About Mission & Vision Executive LeadershipBoard of Directors Business Development Our HeritageHome Science Back Overview Pipeline Programs Back Overview KRAS Inhibitors Back Overview KRAS G12C Inhibitor KRAS G12D Inhibitor Sitravatinib PRMT5 Inhibitor Clinical Trials Presentations & Publications Patients & Caregivers ImpactResponsibility Back Overview Mirati Gives Transparency Diversity, Equity & Inclusion Sponsorships & Grants Stories About Back OverviewMission & Vision Executive LeadershipBoard of Directors Business Development Our HeritageInvestors & Media Back Overview Careers Contact Us Investor & Media Relations Overview Resources Information Request Form Email Alerts Investor Contacts Overview Resources Information Request Form Email Alerts Investor Contacts Corporate Overview Mirati Therapeutics Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer. Contact Us Investor Relations Temre Johnson[email protected] (858) 332-3562Media Relations Priyanka Shah[email protected] (908) 447-6134Quick Links Information Request Form Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Mirati Therapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Mirati Therapeutics Inc. to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options * News Events & Presentations Quarterly Reports Annual Reports SEC Filings Unsubscribe Email Alert Sign Up ConfirmationFacebook Twitter Linkedin © Copyright - Mirati Therapeutics, Inc. 1-844-MIRATI-1 (1-844-647-2841) [email protected] Terms of Use Privacy Cookies Purchase Order Terms Expanded access Community Guidelines Terms of Use | Privacy | Cookies | Purchase Order Terms Expanded access | Community GuidelinesPowered By Q4 Inc. 5.122.0.3 (opens in new window) Mirati is now a Bristol Myers Squibb company Select Accept for Information about Mirati. To learn more about Bristol Myers Squibb Click Here...